Soleil Boughton Sells Shares of Hims & Hers Health

Soleil Boughton, the Chief Legal Officer at Hims & Hers Health, Inc., sold 42,261 shares of the company on June 15, 2026. This transaction was not part of a pre-planned sale. Hims & Hers Health trades on the NYSE under the ticker HIMS.

Other Institutional Activity in Hims & Hers Health

Several institutional investors have also been active in Hims & Hers Health. BlackRock, Inc. reduced its holdings by 236,346 shares, ending with 26,337,158 shares valued at approximately $546.76 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both acquired new positions, adding 10,183,813 and 9,339,711 shares respectively, valued at $211.42 million and $193.89 million. Morgan Stanley significantly increased its stake by 4,959,856 shares, bringing its total to 8,889,088 shares worth about $184.54 million. Meanwhile, State Street Corp added 154,498 shares, totaling 7,460,023 shares valued at $154.87 million.

Hims & Hers Health, Inc. Stock Up 9.1%

Shares of NYSE:HIMS traded near $31.47. Hims & Hers Health has a market cap of $7.28 billion and a forward P/E ratio of 35.36, indicating expectations for future earnings. The stock's beta is 2.398, suggesting higher volatility compared to the market. Over the past year, the stock has ranged from a low of $13.74 to a high of $70.43. The 50-day moving average is $26.07, while the 200-day moving average is $33.44. The company maintains a current ratio of 1.69 and a quick ratio of 1.46, with a debt-to-equity ratio of 253.73.

Recent Earnings

Hims & Hers Health reported revenue of approximately $2.37 billion, showing a growth of 3.8%. However, the company posted a net margin of -0.56% and a return on equity of -2.66%, indicating it is not currently profitable. The next earnings report is expected on August 10, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

In addition to Boughton's sale, other insiders have been active. Mohamed Elshenawy, the CTO, sold 30,040 shares at $31.50 each on June 17, 2026, as part of a planned sale. Irene Becklund, PAO, sold 4,490 shares at $31.50 and 7,573 shares at $30.25 on June 17 and June 16, respectively, both as planned transactions. Michael Chi, the COO, also sold 14,027 shares at $31.50 on June 17, 2026, under a planned sale. Notably, Mohamed Elshenawy made a significant purchase of 282,597 shares on June 15, 2026.

Analysts Set New Price Targets

On May 26, 2026, B of A Securities maintained a hold rating with a $25.00 price target. Truist Securities also maintained a hold rating with a $23.00 target on May 22, 2026. JP Morgan and Needham both have a buy rating, with targets of $33.00 and $35.00, respectively, as of May 12, 2026. The consensus among 14 analysts is a hold, with a mean target price of $26.61.

About Hims & Hers Health

Hims & Hers Health, Inc. is a healthcare company headquartered in San Francisco, California. It operates a platform that connects consumers with licensed healthcare professionals, offering a variety of health and wellness products and services. The company serves markets in the United States, the United Kingdom, Canada, and several European countries. Under the leadership of CEO Andrew Dudum, Hims & Hers provides prescription and non-prescription products, focusing on areas like skincare, sexual health, and hair care.

Bottom Line

Soleil Boughton's recent sale of Hims & Hers Health shares is part of a larger trend of insider transactions at the company. Investors and analysts continue to monitor the stock, which has shown significant volatility over the past year. The company's financials indicate room for improvement, especially with its current lack of profitability. As a reminder, insider transactions like these are reported after the fact and may not reflect current holdings.